Product Description
Eltrombopag, an orally administered, small-molecule non-peptide thrombopoietin receptor agonist, selectively binds to the transmembrane domain of the thrombopoietin receptor on the surface of platelets, megakaryocytes and megakaryocyte precursor cells. The drug acts via the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway to activate megakaryocyte proliferation and differentiation in bone marrow progenitor cells, similar to those observed with endogenous thrombopoietin. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19368418/)
Mechanisms of Action: TPO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Bangladesh, China, Czech Republic, France, Germany, Japan, South Korea, Switzerland, Taiwan
Active Clinical Trial Count: 16
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anemia, Aplastic
Phase 2: Acute Myeloid Leukemia|Graft vs Host Disease|Lymphoma|Myelodysplastic Syndrome|Preleukemia|Purpura, Thrombocytopenic, Idiopathic|Stem Cell Transplant|Thrombocytopenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| EIT | P2 |
Recruiting |
Thrombocytopenia|Purpura, Thrombocytopenic, Idiopathic |
2025-08-31 |
50% |
2025-02-19 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
| CETB115L11201 | P2 |
Active, not recruiting |
Preleukemia|Myelodysplastic Syndrome |
2025-04-26 |
50% |
2025-05-31 |
Primary Completion Date|Primary Endpoints|Treatments |
| EPBSCH | P2 |
Recruiting |
Stem Cell Transplant|Lymphoma |
2025-03-31 |
74% |
2024-01-03 |
Primary Endpoints|Treatments |
| EPAG2015 | P2 |
Active, not recruiting |
Acute Myeloid Leukemia |
2022-06-15 |
72% |
2024-11-01 |
|
| REGALIA | P2 |
Active, not recruiting |
Graft vs Host Disease |
2021-11-06 |
2022-03-13 |
Treatments |
|
| EMAA | P3 |
Completed |
Anemia, Aplastic |
2025-01-30 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| jRCT2021210004 | P2 |
Recruiting |
Myelodysplastic Syndrome |
2025-03-31 |
|||
| JapicCTI-205435 | P2 |
Active |
Anemia, Aplastic |
2024-12-31 |
|||
| CTR20200922 | P2 |
Completed |
Anemia, Aplastic |
2024-12-06 |
2025-04-29 |
||
| iROM2 | P2 |
Completed |
Purpura, Thrombocytopenic, Idiopathic|Thrombocytopenia |
2024-04-11 |
50% |
2024-10-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| XPAG-ITP | P2 |
Completed |
Thrombocytopenia|Purpura, Thrombocytopenic, Idiopathic |
2023-09-22 |
50% |
2025-03-18 |
|
| 2015-000929-37 | P2 |
Completed |
Acute Myeloid Leukemia |
2023-07-16 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| CTR20192327 | P2 |
Completed |
Anemia, Aplastic |
2023-05-17 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| SOAR | P2 |
Active, not recruiting |
Anemia, Aplastic |
2023-04-18 |
50% |
2025-06-14 |
Treatments |
| JapicCTI-205271 | P2 |
Active |
Purpura, Thrombocytopenic, Idiopathic |
2021-03-31 |
|||
| 2023-505788-35-00 | P2 |
Not yet recruiting |
Thrombocytopenia|Purpura, Thrombocytopenic, Idiopathic |
2028-01-13 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/04/2025 |
News Article |
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference |
|
05/16/2025 |
News Article |
Royalty Pharma Completes the Acquisition of Its External Manager |
|
05/13/2025 |
News Article |
Royalty Pharma to Present at Upcoming Investor Conferences |
|
05/12/2025 |
News Article |
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition |